Clotrimazole 1% OTC monograph inclusion opposed in McKenna & Cuneo petition.
This article was originally published in The Tan Sheet
Executive Summary
CLOTRIMAZOLE 1% FORMULATION DIFFERENCES MAY EFFECT SAFETY AND EFFICACY, the Washington, D.C.-based law firm McKenna & Cuneo states in an April 22 citizen petition submitted on behalf of an undisclosed client. The petition opposes Schering-Plough's recent request that FDA revise the final monograph for topical antifungal OTC drug products to include clotrimazole 1% ("The Tan Sheet" Dec. 16, 1996, p. 8).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning